Möchten Sie immer auf dem neuesten Stand bleiben?

New York, USA, April 13, 2026 (GLOBE NEWSWIRE) -- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such...

ROCKVILLE, Md., April 13, 2026 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) announced today its 2026 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership...

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Smart Packaging and Electronic Patient Information (May 21, 2026)" training has been added to ResearchAndMarkets.com's offering.This course will...

Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model  Collaboration combines Regeneron’s leading antibody...

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights...

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly...

Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants L'approbation dans l'urticaire chronique spontanée...

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is...

New York, USA, April 09, 2026 (GLOBE NEWSWIRE) -- Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight The...

STUDIO CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- As this year’s Myeloma Action Month came to a close, the International Myeloma Foundation (IMF) was truly grateful for the incredible support...